Montefiore Einstein Comprehensive Cancer Center

The Bronx, New York 10467

12 studies enrolling now · 14 studies all time

What they study most

Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia Refractory, Breast Cancer, Cancer Patients, Cancer of the Prostate, Colorectal Neoplasms, ER+ Breast Cancer, Endometrial Cancer, Germ Cell Tumor, HER2 Positive Breast Cancer, HER2-low Breast Cancer, HER2-negative Breast Cancer

Studies at this site

• A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer — Recruiting now
• A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy — Recruiting now
• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. — Recruiting now
• Circulating Tumor DNA — Recruiting now
• Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors — Recruiting now
• GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC — Recruiting now
• Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia — Recruiting now
• Use of a Comprehensive, Mobile Application to Assist Cancer Patients With Diet, Nutrition and Activity — Recruiting now
• A Study of CTD402 in T-ALL/LBL Patients — Recruiting now
• TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd — Recruiting now
• Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib — Recruiting now
• A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes — Recruiting now
• A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Running, not enrolling
• A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody — Running, not enrolling